The Key Events Dose-Response Framework: A Cross-Disciplinary Mode-of-Action Based Approach to Examining Dose-Response and Thresholds by JULIEN, ELIZABETH et al.
Critical Reviews in Food Science and Nutrition, 49:682–689 (2009)
Copyright C     Taylor and Francis Group, LLC
ISSN: 1040-8398
DOI: 10.1080/10408390903110692





ELIZABETH JULIEN,1∗ ALAN R. BOOBIS,2 STEPHEN S. OLIN1, and THE ILSI
RESEARCH FOUNDATION THRESHOLD WORKING GROUP3
1ILSI Research Foundation, Washington, DC, USA
2Department of Experimental Medicine and Toxicology, Imperial College London, London W12 0NN, UK
3See Table 1
The ILSI Research Foundation convened a cross-disciplinary working group to examine current approaches for assessing
dose-response and identifying safe levels of intake or exposure for four categories of bioactive agents—food allergens,
nutrients,pathogenicmicroorganisms,andenvironmentalchemicals.Thiseffortgeneratedacommonanalyticalframework—
the Key Events Dose-Response Framework (KEDRF)—for systematically examining key events that occur between the initial
dose of a bioactive agent and the effect of concern. Individual key events are considered with regard to factors that inﬂuence
the dose-response relationship and factors that underlie variability in that relationship. This approach illuminates the
connection between the processes occurring at the level of fundamental biology and the outcomes observed at the individual
andpopulationlevels.Thus,itpromotesanevidence-basedapproachforusingmechanisticdatatoreducerelianceondefault
assumptions, to quantify variability, and to better characterize biological thresholds. This paper provides an overview of the
KEDRF and introduces a series of four companion papers that illustrate initial application of the approach to a range of
bioactive agents.
Keywords low dose dose-response, uncertainty, variability, default extrapolation
INTRODUCTION
Protection of the general population and susceptible subpop-
ulations from bioactive agents that may pose health risks is a
primarypublichealthchallenge.Theagentsofpotentialconcern
include food allergens, pathogens, environmental chemicals
(i.e., chemicals introduced into the environment via industrial
processes, consumer products, etc.), and high intakes of certain
nutrients. For each of the many potential exposure scenarios—
chemical contaminants in consumer products, pathogens in wa-
ter, allergens in food, nutrients in dietary supplements, etc.—
public health authorities must make judgments regarding “safe
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levels”(i.e.,levelsofexposureorintakewhereriskisconsidered
negligible).
Ideally, determinations regarding safe levels are informed by
a thorough knowledge of the dose-response relationship for the
agentandpopulationofconcern.Inpractice,however,decisions
mustoftenbemadewithoutcompleteinformation,requiringthe
use of extrapolation and assumptions. Also, each type of bioac-
tive agent has its own particular challenges in assessing dose-
response. In the case of pathogenic microorganisms, for exam-
ple, the bioactive agent may multiply after intake, substantially
increasingthedose.Withessentialnutrients,adverseeffectsmay
potentially result from deﬁcient intake as well as excess intake.
With food allergens, both the nature and the severity of the re-
sponsetoagivendosevaryconsiderablyevenwithinthesuscep-
tible subpopulation. In general, discipline-speciﬁc approaches
foridentifyingsafelevelshaveevolved.However,thedisciplines
share some fundamental challenges regarding dose-response
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assessment, and there is a common need to advance methodol-
ogy and to harmonize approaches to the extent possible.
To address this need, the International Life Sciences Institute
Research Foundation (ILSI RF) convened a working group with
expertsfromarangeofdisciplines,includingcancerriskassess-
ment, microbial risk assessment, food allergies, nutrition, and
dose-response modeling. Working group participants are listed
in Table 1.
The members of the group were asked to consider two main
questions:
• How can we make better use of current data and methods to
advance understanding of dose-response relationships, espe-
cially with regard to dose levels relevant to public health?
• Howcanwemakepracticaluseofanimprovedunderstanding
of dose-response for assessing risk, developing regulatory
standards, designing nutrition programs, etc.?
Initial discussions by the group considered a range of agent-
endpointcombinations(e.g.,chloroformandlivercarcinogenic-
ity, Listeria monocytogenes and fetal death), focusing on what
is known about the fundamental biology. The cross-disciplinary
approach promoted a fresh look at long-held assumptions and
traditional approaches to assessing dose-response. In these ini-
tial discussions it became clear, however, that the term “thresh-
old” is commonly used to refer to several diverse concepts.
Thus, deﬁnitions were adopted for terms used in this effort, in
particular,thebiologicalthresholdandthepopulationthreshold.
These are discussed in the Appendix.
Despite the wide range of agents considered, the group came
to develop and adopt a common analytical framework that is
basedonmode-of-actionconcepts.Thispaperdescribesthisan-
alyticalapproach,referredtoasthe“KeyEventsDose-Response
Framework,” and provides a summary of the general ﬁndings
and conclusions from this effort.
THE KEY EVENTS DOSE-RESPONSE FRAMEWORK
Relationship to Mode-of-Action
The Key Events Dose-Response Framework (KEDRF) is
largely based on “mode-of-action” (MOA) concepts, where
MOA refers to the fundamental biological events and processes
that underlie the effect of a bioactive agent. MOA is relevant
to the range of life science disciplines, and investigations into
MOA have a long history in pharmacology, toxicology, and
medicine (DuBois et al., 1949; Bueding and Mansour, 1957;
Daniel et al., 1966; Eldefrawi et al., 1970, Erlanger and Goode,
1967). In the ﬁeld of risk assessment, MOA information has
been particularly useful for evaluating potential chemical car-
cinogens (Cohen, 1995; Sonich-Mullin, 2001; EPA, 2005). In
recent years, the use of MOA information for risk assessment
purposes has expanded substantially with the development of
frameworks for evaluating the human relevance of MOA in ex-
perimental animals for carcinogens (Cohen et al. 2003; Klaunig
et al., 2003, Meek et al., 2003; Boobis et al., 2006) and for
non-cancer effects (Seed et al., 2005; Boobis et al., 2008).
In the ﬁeld of chemical risk assessment, MOA analysis starts
with the identiﬁcation of the speciﬁc effect of concern, and then
identiﬁes the series of key events that lead to this effect. The
term “key event” has been deﬁned as an empirically observable
precursor step that is itself a necessary element of the MOA, or
a biologically based marker for such an element (Sonich-Mullin
et al., 2001). Hence, a key event is a necessary, though not a
sufﬁcient, step in a process that results in a speciﬁc adverse
effect. In some MOA assessments for evaluating potential car-
cinogens, the focus has been on dynamic events. For example,
in the EPA Guidelines for Carcinogen Risk Assessment (EPA,
2005), the toxicokinetic processes that lead to formation of the
active agent or its distribution to the target tissue are considered
in estimating dose, but they are not considered as part of the
mode of action.
Similar to a MOA analysis, the ﬁrst step in a Key Events
Dose-Response Analysis (KEDRA) involves specifying the ef-
fect of concern for the agent of interest.1 Also, similarly, the
Key Events in a KEDRA are necessary precursor steps. But, as
illustrated by some of the papers in this series, a KEDRA may
also include substantial consideration of kinetic events (i.e., ab-
sorption, distribution, metabolism, etc.) in addition to dynamic
eventsinthetargettissue.ThenovelcontributionoftheKEDRF
1Note that the KEDRA approach may also be applied to categories of agents or
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Figure 1 Factors operating at the level of Key Events. In addition to dose, other factors may inﬂuence the outcome of an individual event. In combination, they
may affect the likelihood of progression to the next event, or they may affect the magnitude of the ultimate response of concern.
is that it outlines a systematic analytical approach to examin-
ing in detail the fundamental determinants of dose-response
relationships, including determinants of variability in such rela-
tionships. The KEDRF provides a foundation for more rigorous
and quantitative descriptions of dose-response at dose levels
relevant to public health. Moreover, this analytical approach,
which focuses at the level of key events, is applicable across a
range of bioactive agents.
Framework Elements and Process
As noted above, one of the ﬁrst tasks in conducting a KE-
DRAistodescribethepathwayofkeyeventsoccurringbetween
the initial exposure and the effect of concern. The analysis then
proceeds to examine what is known about the dose-response
relationship for each individual event, including whether there
is scientiﬁc evidence for the existence of a threshold at any of
the events. Generally, the key events pathway is composed of
several kinetic and dynamic steps, which can be described with
respect to relevant receptors, enzymes, etc. As shown in Fig. 1,
at each event in the pathway several elements can be examined
with regard to their inﬂuence on the dose-response relationship.
These elements include i) the level and frequency of the dose
(for the agent itself, its metabolite, or ultimate effector); ii) the
speciﬁc biological interaction that occurs; and iii) the range of
factors that may affect outcome of the interaction. These factors
include various physiological mechanisms that serve to control
ormaintainthenormalphysiological environment,forexample,
homeostatic, repair, adaptive or immune mechanisms. In addi-
tion, there are a variety of host characteristics (for example, life
stage, disease state, genetic makeup) that correspond to, and un-
derlie, the inter- and intra-individual variability often observed
in the dose-response. Note that one way in which these host
characteristics may contribute to variability is by altering the
effectiveness of physiological control mechanisms at individual
events in the pathway.
Understandingtheinterplayofthevariousfactors(dose,con-
trol mechanisms, host characteristics) at the level of individual
events in the pathway is a prerequisite to reﬁning the under-
standing of dose-response for both individuals and populations.
In theory, it should be possible to describe a dose-response re-
lationship for each individual event in the pathway, and to study
i) how these individual dose-response relationships combine
to generate the overall dose-response curve for the effect of
concern, and ii) how interspecies, interindividual, and intrain-
dividual differences affect speciﬁc events in the pathway, and
consequently alter dose-response relationships.
A schematic of the overall Key Events Dose-Response
Framework is shown in Fig. 2. While the overall pathway con-
sists of a chain of conditional events, certain events may be
considered “control points” in that they engage one or more
mechanisms(homeostatic,repair,etc.)tocontrolormaintainthe
physiological environment. In order for the cascade of events to
proceed toward the ultimate effect of concern, it appears these
controlmechanismsmustbeoverwhelmedbydose,orotherwise
fail.Understandingtheconditions(i.e.,thespeciﬁccombination
of dose level, homeostatic capacity, etc.) under which control
can be lost is likely central to characterizing thresholds, in-
cluding variability in their values. Theoretically, certain controlEXAMINING DOSE RESPONSE AND THRESHOLDS 685
Figure 2 The Key Events Dose-Response Framework organizes available information on the multiple kinetic and dynamic events that occur between an initial
dose and the effect of concern. Events are indicated generically here; but, for a given pathway, many speciﬁc kinetic and dynamic events may occur.
points may play an especially critical role in a given pathway,
i.e., they may be “determining events.” The outcome of a de-
termining event greatly inﬂuences the likelihood of the ultimate
effect of concern; it tends to “determine” whether the effect will
occur given the initial dose.2 Starting with this framework, the
KEDRF proceeds to ask questions about individual events, and
also about the overall series of events.
Questions about individual events may include:
• What physiological mechanisms (homeostatic, immune re-
sponse, adaptive, or repair) may come into play at this event,
and how do they affect the outcome of the event? Can a “high
enough” dose potentially overwhelm such mechanisms? How
could this be further studied?
• What host characteristics, for example, life stage, disease
state, genetic makeup, exposure patterns, may modify (di-
minish or enhance) effectiveness of homeostatic or other such
mechanisms at this event? To what extent might these factors
explain the inter- and intra-individual variability? How could
this be further studied?
• What data would be needed to better characterize the dose-
response relationship at this individual event? What evidence
would be needed to support or refute the existence of a bio-
logical threshold at this event? What data would be needed to
characterize the location/value of a threshold?
2The concept of a determining event is discussed further in a separate paper in this
series (Ross et al., 2009).
Questions about the overall pathway of events may then be
asked, including:
• Which events appear to be “control points,” i.e., they engage
speciﬁc mechanisms that may inﬂuence the ultimate outcome
(either the magnitude of the outcome, or the probability of the
outcome)?
• Is any particular event a potential “determining event,” i.e., its
outcome has a disproportionate inﬂuence (compared to other
events) on whether the ultimate effect of concern occurs?
• Does the dose-response relationship at any particular event
appear to drive the shape, slope, or position of the overall
dose-response curve?
• Whatmetabolitesorotherbiomarkerswouldindicatethatcon-
trol points have failed? Are these, potentially, early indicators
of toxicity? How could they be studied?
The questions raised in the KEDRF may not generate ready
answers; however, this type of analysis helps identify the data
and knowledge most critically needed to better understand the
determinants of the overall dose-response relationship.
Value of the Key Events Dose-Response Framework
The KEDRF is an analytical approach for evaluating cur-
rently available data and for focusing future research. It pro-
motes an iterative scientiﬁc process that can be expected to686 JULIEN ET AL.
continually strengthen the scientiﬁc basis for public health
decision-making and regulatory standards. More speciﬁcally,
thisconceptualframeworkisexpectedtoadvancedose-response
assessment in the following ways.
Reﬁning Understanding of Dose-Response and Biological
Thresholds
The KEDRF approach “deconstructs” the overall dose-
response relationship into its essential elements—its Key
Events, and the multiple factors inﬂuencing those events (i.e.,
dose level and frequency, homeostatic mechanisms, etc.). This
systematic analytical approach sheds light on the fundamental
determinantsofthedose-responsecurve.Thus,theKEDRFpro-
vides a strategy for substantially reﬁning dose-response assess-
ment.Thisapproachalsopromotesnewinsightsandhypotheses
regarding drivers of the dose-response relationship, early indi-
cators of increased risk of an adverse effect (e.g., biomarkers
indicating loss of homeostatic control) and ﬁrst indicators of the
effect.
Reducing Uncertainty in Population Thresholds
Uncertainty in population dose-response curves comes from
many sources—inter- and intra-individual variability, inter-
speciesdifferences,modeluncertainty(e.g.,extrapolationtolow
doselevels),etc.Fundamentally,thisuncertaintyisduetoalack
of knowledge regarding exactly how the individual biological
processes that underlie dose-response are affected by species,
interindividual differences, etc. By promoting examination of
these issues at their fundamental level, the KEDRF provides a
bridge between available mechanistic data and practical use of
such data to reﬁne dose-response assessment.
Leveraging Data and Knowledge
The KEDRF approach promotes the best use of all avail-
able science. It complements and builds on the standard em-
pirical, mechanistic, and modeling approaches currently used
to study dose-response. Such approaches inform and reﬁne the





The KEDRF also leverages data across disciplines, and
acrossbioactiveagents.Itprovidesaplatformforsharingknowl-
edge about cellular and molecular pathways that are relevant to
diverse agents. In addition, the KEDRF approach helps draw
connections between underlying biological processes and the
effects observed at the population level. This leverages knowl-
edge across distinct biological levels (e.g., the use of epi-
demiological methods to corroborate mechanistic studies of
biomarkers).
General Conclusions
As noted initially, twobroad questions wereposed at theout-
set of this ILSI RF project: How can we utilize current science
to improve understanding of dose-response, and how can we
translate improved understanding into practical advances in risk
assessment and public health decision-making? The working
group answered with the development of an analytical frame-
work, a way of thinking about dose-response that suggests a
path forward. The KEDRF illuminates the connections between
theprocessesoccurringatafundamentalbiologicallevelandthe
outcomes observed at the individual and population levels. It is
a mode-of-action, evidence-based approach that promotes use
of data on key events to characterize dose-response relation-
ships, including thresholds, and to reduce reliance on default
assumptions.
It is important to note that the KEDRF’s analytical approach
complements the vision and strategy for toxicity testing out-
linedinarecentNRCreport(NationalResearchCouncil,2007).
While the NRC report focuses on chemicals, the developments
it discusses in bioinformatics, systems biology, epigenetics, and
computational toxicology are relevant to the range of bioactive
agents considered in the present study. These developments are





ment for the range of agents of concern in public health and for
informing the assessment of one agent by knowledge obtained
from the assessment of others.
Initial Application of the Key Events Dose-Response
Framework
The next four papers in this series describe how the KEDRF
may be applied to a range of bioactive agents including DNA-
reactive and non DNA-reactive carcinogens, endocrine disrup-
tors, microorganisms, food allergens, and nutrients (Boobis
etal.,2009;Buchananetal.,2009;Tayloretal.,2009;Rossetal.,
2009). Some of these studies consider speciﬁc agents (chlo-
roform, an environmental toxicant; Listeria monocytogenes, a
pathogenic microorganism; and Vitamin A, a nutrient). These
agents were selected to illustrate the approach, and were not
intended to be representative of all agents in their class. Other
studies in this series discuss the application of the KEDRF
approach to broad categories of agents (DNA-reactive carcino-
gens, food allergens, and endocrine disruptors). While most of
the case studies consider agents found in food products, the KE-
DRF should be readily applicable to other scenarios and routes
of exposure as well. Also, while the case studies consider only
effects from excess intake or exposure, the KEDRF should also
be applicable to examining the effects from inadequate intake
of nutrients.EXAMINING DOSE RESPONSE AND THRESHOLDS 687
The general ﬁnding from this initial investigation is that the
KEDRF is a promising analytical approach applicable to a wide
range of bioactive agents. As will be seen in the documents
that follow, the principal value of the approach at this time
differs depending on the type of agent. For example, for food
allergens, clinical data clearly demonstrate the presence of bi-
ological thresholds. The interindividual variability in threshold
levels is remarkable, however. Thus for allergens, the KEDRF
is likely to be especially valuable in pinpointing speciﬁc biolog-
ical processes responsible for variability, or perhaps biomarkers
that can differentiate levels of sensitivity. In contrast to food
allergens, for invasive or toxicoinfectious microorganisms, the
widely accepted assumption is that ingestion of even a single
pathogenic cell has the potential to cause illness. Even within
susceptible subpopulations, however, ingestion does not lead
invariably to adverse effects. A rigorous examination of the dy-
namic interplay between the pathogen and the host at speciﬁc
key events is needed to tease out the pathogen and host vari-
ables that determine whether illness will occur. For nutrients,
kinetic processes designed to accommodate daily variations in
dose (nutrient intake) may play an especially critical role in
determining whether high intake levels lead to adverse effects.
Further investigation of how these processes operate at control
points in the key events cascade should contribute important in-
sightsforcharacterizingtolerableupperlevels.Forcarcinogens,
the KEDRF provides further insight into the types of informa-
tion that would obviate the need for the default assumption of
linear low-dose extrapolation in the risk assessment of a chemi-
cal. It would also enable better integration of chemical-speciﬁc
information into such assessments.
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APPENDIX
Threshold Concepts and Deﬁnitions
Theterm“threshold”isusedfrequentlyintheﬁeldsofhealth
risk assessment, food safety, and nutrition. Multiple regulatory
agencies and public health organizations use the term, and in
some cases deﬁne the term. Some examples of deﬁnitions are
provided in Table A-1.
As is apparent from Table A-1, the term “threshold” is com-
monly interpreted to mean a dose below which no adverse ef-
fect is observed or expected. It is important to recognize both
aspects—observation and expectation—as observation alone
usually cannot establish a threshold, due to limitations of the
sensitivity of measurement methods. “Expectation” of a thresh-
old is based on knowledge of the underlying biology of the
relevant processes.
Also, none of the deﬁnitions listed in Table A-1 differentiate
between two distinct but related concepts, biological thresholds
and population thresholds. Thus, for purposes of the present
project, the ILSI RF working group developed two deﬁnitions.
Asusedinthisproject,abiologicalthresholdisthetransition




the actual point of transition between two qualitatively different
physiological states, is determined by fundamental properties
of an organism, whereas the values of NOELs are affected by
studydesign,forexample,doseselectionorsamplesize.NOELs
may,however,helptolocatethedoserangeinwhichabiological
threshold likely exists, that is, a biological threshold for a given
effectisgenerallyassumedtobegreaterthanitsNOELbutlower
than its Lowest-Observed-Effect-Level (LOEL). However, due
to statistical variation and lack of sensitivity or precision in
3“Dose” may refer to the initial dose, exposure or intake level – or to an internal dose
of the parent compound, its metabolite, or a resulting effector.
Table A-1 Some authoritative deﬁnitions of “threshold”
Authoritative Source Deﬁnition of “Threshold”
International Programme on Chemical





Threshold: Dose or exposure
concentration of an agent below
which a stated effect is not




Threshold: The dose or exposure
below which no deleterious
effect is expected to occur.




Two deﬁnitions are provided:
Threshold: The dose or exposure
level below which a signiﬁcant
adverse effect is not expected.
Threshold: T h el o w e s td o s eo fa
chemical at which a speciﬁed
measurable effect is observed
and below which it is not
observed.
measuring techniques, it is seldom possible to identify the exact
location of a biological threshold. Biological thresholds can be
further described by the following characteristics:
• Biological thresholds can occur at various levels of biological
organization, for example, at subcellular, cellular, tissue, and
organism levels.
• There is a fundamental interconnection between biological
thresholds and the maintenance of homeostasis. Homeostatic
feedback mechanisms engage in response to a perturbation
when physiological conditions exceed a set point, and dis-
engage when the physiological environment is restored to
within tolerable parameters. The points at which such mecha-
nisms engage, and then disengage, are examples of biological
thresholds.
As used in this project, a population threshold is an estimate
of a biological threshold for a speciﬁed effect that holds for
a speciﬁed proportion of a deﬁned population. Thus, at doses
above the population threshold, y% of the population will show
the response of interest, and (100-y)% will not. In theory, the
population threshold is derived from the distribution of biologi-
calthresholdsforindividualsinthepopulation;thusittakesinto
accountinterindividualvariability(ingeneticmakeup,exposure
patterns, disease states, etc), as illustrated in Fig. A-1.EXAMINING DOSE RESPONSE AND THRESHOLDS 689
Figure A1 Theoretical population distribution curve of individual biological thresholds for a speciﬁed effect. The ordinate shows the cumulative percentage
(“y”) of individuals with a biological threshold ≤ the corresponding value of “x”, on the abscissa.